Future Virology

Papers
(The TQCC of Future Virology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections85
The role of artificial intelligence in tackling COVID-1965
A comprehensive review about SARS-CoV-257
The role of miRNAs in COVID-19 disease56
A brief review on DNA vaccines in the era of COVID-1947
The divergence between SARS-CoV-2 and RaTG13 might be overestimated due to the extensive RNA modification44
Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach44
Relationship between IL-6 and COVID-19: to be considered during treatment41
Transmission and clinical characteristics of asymptomatic patients with SARS-CoV-2 infection39
Possible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptor38
The potential of lactoferrin, ovotransferrin and lysozyme as antiviral and immune-modulating agents in COVID-1935
Perversely expressed long noncoding RNAs can alter host response and viral proliferation in SARS-CoV-2 infection32
Virtual screening of immunomodulatory medicinal compounds as promising anti-SARS-CoV-2 inhibitors31
Natural selection on synonymous mutations in SARS-CoV-2 and the impact on estimating divergence time27
Toll-like receptor 4 in COVID-19: friend or foe?26
Fast evolution of SARS-CoV-2 driven by deamination systems in hosts21
Potential anti-COVID-19 activity of Egyptian propolis using computational modeling20
TheMtb-HIV syndemic interaction: why treatingM. tuberculosisinfection may be crucial for HIV-1 eradication20
COVID-19 in homeless populations: unique challenges and opportunities19
Xerostomia (dry mouth) in patients with COVID-19: a case series19
Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases18
Predictive values of biochemical markers as early indicators for severe COVID-19 cases in admission17
Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis17
Pros and cons of the application of evolutionary theories to the evolution of SARS-CoV-215
A systematic review and meta-analysis of the sensitivity of antibody tests for the laboratory confirmation of COVID-1915
Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA15
Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future14
Genetic and pathogenic characterization of SARS-CoV-2: a review13
Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis13
Pandemic response management framework based on efficiency of COVID-19 control and treatment12
In silico identification of conserved cis-acting RNA elements in the SARS-CoV-2 genome12
Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy12
Asymptomatic carriers of coronavirus disease 2019 among healthcare workers in Isfahan, Iran11
Andrographolide induces anti-SARS-CoV-2 response through host-directed mechanism: anin silicostudy11
The COVID-19 pandemic: an increased risk of rheumatoid arthritis10
Identifying asymptomatic cases during the mass COVID-19 vaccination campaign: insights and implications for policy makers10
High-value laboratory testing for hospitalized COVID-19 patients: a review10
Mechanisms of infection by SARS-CoV-2, inflammation and potential links with the microbiome10
An overview of sex hormones in relation to SARS-CoV-2 infection9
Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery9
Comparative sequence analysis of SARS-CoV-2 suggests its high transmissibility and pathogenicity9
Prediction and analysis of key protein structures of 2019-nCoV9
COVID-19 and coronaviral hepatitis: evidence of collateral damage8
In-hospital clinical complications of COVID-19: a brief overview8
Targeting SARS-CoV-2 nonstructural protein 15 endoribonuclease: anin silicoperspective8
Susceptibility of the Iranian population to severe acute respiratory syndrome coronavirus 2 infection based on variants of angiotensin I converting enzyme 28
What is the intermediate host species of SARS-CoV-2?8
An analysis of inhibition of the severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase by zinc ion: an in silico approach8
V483A: an emerging mutation hotspot of SARS-CoV-27
Massive third-wave COVID-19 outbreak in Bangladesh: a co-epidemic of dengue might worsen the situation7
A new perspective of the chemistry and kinetics of inactivation of COVID -19 coronavirus aerosols7
Phylogenetic and whole genome analysis of first seven SARS-CoV-2 isolates in Bangladesh7
Association of anemia and COVID-19 in hospitalized patients7
Brain tissue-resident immune memory cells are required for long-term protection against CNS infection with rabies virus7
Detection of SARS-CoV-2 in the sewerage system in Tunisia: a promising tool to confront COVID-19 pandemic7
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes7
SARS-CoV-2 likely targets cellular PDZ proteins: a common tactic of pathogenic viruses7
HPV and its high-risk genotypes in Middle Eastern countries: a meta-analysis7
Structural analysis of Spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations7
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise7
Can natural detergent properties of bile acids be used beneficially in tackling coronavirus disease-19?6
Research progress in vertical transmission of SARS-CoV-2 among infants born to mothers with COVID-196
Natural killer cells in COVID-19: from infection, to vaccination and therapy6
Airborne transmission of SARS-CoV-2 disease (COVID-19)6
Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent6
Nothing in SARS-CoV-2 makes sense except in the light of RNA modification?6
Investigation of the relationship between inherited thrombophilia and novel coronavirus pneumonia6
SARS-CoV-2 direct real-time polymerase chain reaction testing in laboratories with shortage challenges6
Detection and predictors of anti-SARS-CoV-2 antibody levels in COVID-19 patients at 8 months after symptom onset5
Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis5
Rare cutaneous manifestation of COVID-19 infection and Pfizer-BioNTech COVID-19 vaccine with a unique pattern similarity5
Dengue outbreak 2018 in district Shangla KPK; clinical features and laboratory markers of dengue virus infection5
Reinfection and reactivation of SARS-CoV-25
Scouting the receptor-binding domain of SARS coronavirus 2: a comprehensive immunoinformatics inquisition5
In silico study of potential anti-SARS cell entry phytoligands from Phlomis aurea: a promising avenue for prophylaxis5
Erythema multiform-like lesions in a patient infected with SARS-CoV-2: a case report5
A flow virometry process proposed for detection of SARS-CoV-2 and large-scale screening of COVID-19 cases5
Thoughts on detecting tissue distribution of potential COVID-19 receptors5
Computational guided approach for drug repurposing against SARS-CoV-25
Phylogenomics and phylodynamics of SARS-CoV-2 genomes retrieved from India5
Can anti-parasitic drugs help control COVID-19?5
The role of hepatitis B surface antibodies in HBV infection, disease and clearance4
Evidence-based policies in public health to address COVID-19 vaccine hesitancy4
Reappraisal of trifluperidol against Nsp3 as a potential therapeutic for novel COVID-19: a molecular docking and dynamics study4
Prevalence of HCV and/or HBV coinfection in Iranian HIV-infected patients4
The need for more robust research on the effectiveness of masks in preventing COVID-19 transmission4
Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-194
SARS-CoV-2 nomenclature: viruses, variants and vaccines need a standardized naming system4
The Mu strain: the last but not least circulating ‘variant of interest’ potentially affecting the COVID-19 pandemic4
Elevated levels of procoagulant microvesicles in patients with dengue fever4
The third booster vaccination dose against COVID-19: indications for circulating SARS-CoV-2 variants4
Synthetic antiviral peptides: a new way to develop targeted antiviral drugs4
RT-LAMP is a potential future molecular diagnostic tool for influenza A virus4
In silicodiscovery of non-psychoactive scaffolds inCannabishalting SARS-CoV-2 host entry and replication machinery4
A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program4
Potential drugs against COVID-19 revealed by gene expression profile, molecular docking and molecular dynamic simulation4
LIF and the lung’s stem cell niche: is failure to use LIF to protect against COVID-19 a grave omission in managing the pandemic?4
Investigation of compatibility of severe acute respiratory syndrome coronavirus 2 reverse transcriptase-PCR kits containing different gene targets during coronavirus disease 2019 pandemic4
Association between blood groups and COVID-19 outcome in Iranian patients4
0.048360109329224